Publications by authors named "Ana Clopes"

Claim this Profile
R
Reform of economic evaluation of medicines in Spain: proposals from the Advisory Committee for Pharmaceutical Financing.
Marta Trapero-Bertran, Jaume Puig-Junoy, Emilio J Alegre-Del-Rey, Ana Clopés, Félix Lobo

Gac Sanit· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guideline for the economic evaluation of medicines: a proposal by the Spanish National Health System's Advisory Committee for Pharmaceutical Financing.
Marta Trapero-Bertran, Juan Oliva, Ferrán Catalá-López, Lidia García-Pérez, Lluís Segú

Gac Sanit· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project).
Eduard Fort-Casamartina, Sonia Pernas, Sara Otero, Paula Mate, Núria Gonzalo

J Clin Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Centralization and automation of non-toxic drug reconstitution in the pharmacy: a strengths, weaknesses, opportunities, and threats analysis.
Mirjam Crul, Carlo Polidori, Demis Paolucci, Andrew Lowey, Helle Ølgaard McNulty, Ana Clopes

Int J Pharm Pract· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience.
Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Ricard Mesía

Pharmacol Res Perspect· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution.
Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Javier Martínez

Cancer Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis.
Consuelo Jordán de Luna, Esteve Fernández, Ricard Mesía, Ana Clopés

Clin Transl Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain).
Laura Guarga, Montse Gasol, Anna Reyes, Marta Roig, Enric Alonso

Value Health· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.
Paula Peremiquel-Trillas, Anna Saura-Lázaro, Yolanda Benavente-Moreno, Delphine Casabonne, Eva Loureiro

BMJ Open· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.
Ana Clopes, Montse Gasol, Rosana Cajal, Luis Segú, Ricard Crespo

J Med Econ· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators After Five Rounds (2000-2012).
Gemma Binefa, Montse Garcia, Núria Milà, Esteve Fernández, Francisco Rodríguez-Moranta

Sci Rep· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
Isabel Sánchez-Ortega, Beatriz Patiño, Carmen Muñoz, Montserrat Arnan, Teresa Peralta

J Med Econ· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Position of the hospital pharmacist regarding the use of medication in non-authorised conditions].
Olga Delgado, Francesc Puigventós, Ana Clopés

Farm Hosp· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors.
Margarita Majem, Ramon Salazar, Margarita Garcia, Ana Clopes, Carme Muñoz

J Liposome Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations.
Margarita García, Ana Clopés, Jordi Bruna, María Martínez, Eduard Fort

Cancer Manag Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Impact on budget of new drugs for colorectal cancer treatment].
M Julieta Corral, Ana Clopès, Matilde Navarro, Josep Ramon Germà, Josep Maria Borràs

Med Clin (Barc)· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Rodrigo Martino, José A Pérez-Simón, Estela Moreno, José M Queraltó, Dolores Caballero

Biol Blood Marrow Transplant· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis